Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases

Lisa M. Guirguis, James C. Yang, Donald E. White, Seth M. Steinberg, David J. Liewehr, Steven A. Rosenberg, Douglas J. Schwartzentruber

Research output: Contribution to journalArticle

Abstract

The authors determined the safety and efficacy of recombinant high-dose interleukin-2 administration in patients with brain metastases. This retrospective review included 1,069 patients with metastatic melanoma or renal cell carcinoma who received high-dose interleukin-2 alone or in combination with other immunotherapy or chemotherapy from July 1985-July 2000. All patients were evaluated for both toxicity and response. Only the first exposure to interleukin-2 was considered. Parameters evaluated among the groups included toxicity profiles, reasons for stopping treatment, number of interleukin-2 doses per cycle, and response to therapy. Three patient groups were compared. Group I (n = 27) comprised patients with previously treated brain metastases (surgery or radiation), group 2 (n = 37) comprised patients with untreated brain metastases, and group 3 (n = 1,005) comprised patients without brain metastases. For most comparisons between patients with brain metastases and those without, no significant differences were noted in toxicity profiles or reasons for stopping interleukin-2 therapy. Patients with previously treated brain metastases received fewer interleukin-2 doses per cycle (median, 6.5) than patients with previously untreated brain metastases (median, 7.5) or patients without brain metastases (median, 7.5). Patients with previously treated brain metastases demonstrated an 18.5% overall clinical response to interleukin-2 treatment. However, patients with evaluable (previously untreated) brain metastases had an overall 5.6% response rate, which was less than the 19.8% response rate of patients without brain metastases. Two of thirty-six patients with evaluable brain metastases demonstrated objective regression of intracranial and extracranial disease after receiving interleukin-2. Carefully selected patients with brain metastases can safely receive high-dose interleukin-2, and some can experience a response to treatment at intracranial and extracranial disease sites.

Original languageEnglish (US)
Pages (from-to)82-87
Number of pages6
JournalJournal of Immunotherapy
Volume25
Issue number1
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Interleukin-2
Neoplasm Metastasis
Safety
Brain
Therapeutics
Renal Cell Carcinoma
Immunotherapy
Melanoma

Keywords

  • Brain metastases
  • Interleukin-2
  • Melanoma
  • Safety

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Immunology

Cite this

Guirguis, L. M., Yang, J. C., White, D. E., Steinberg, S. M., Liewehr, D. J., Rosenberg, S. A., & Schwartzentruber, D. J. (2002). Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. Journal of Immunotherapy, 25(1), 82-87. https://doi.org/10.1097/00002371-200201000-00009

Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. / Guirguis, Lisa M.; Yang, James C.; White, Donald E.; Steinberg, Seth M.; Liewehr, David J.; Rosenberg, Steven A.; Schwartzentruber, Douglas J.

In: Journal of Immunotherapy, Vol. 25, No. 1, 2002, p. 82-87.

Research output: Contribution to journalArticle

Guirguis, LM, Yang, JC, White, DE, Steinberg, SM, Liewehr, DJ, Rosenberg, SA & Schwartzentruber, DJ 2002, 'Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases', Journal of Immunotherapy, vol. 25, no. 1, pp. 82-87. https://doi.org/10.1097/00002371-200201000-00009
Guirguis, Lisa M. ; Yang, James C. ; White, Donald E. ; Steinberg, Seth M. ; Liewehr, David J. ; Rosenberg, Steven A. ; Schwartzentruber, Douglas J. / Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. In: Journal of Immunotherapy. 2002 ; Vol. 25, No. 1. pp. 82-87.
@article{512cc29164224436996d93b4ce13aedb,
title = "Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases",
abstract = "The authors determined the safety and efficacy of recombinant high-dose interleukin-2 administration in patients with brain metastases. This retrospective review included 1,069 patients with metastatic melanoma or renal cell carcinoma who received high-dose interleukin-2 alone or in combination with other immunotherapy or chemotherapy from July 1985-July 2000. All patients were evaluated for both toxicity and response. Only the first exposure to interleukin-2 was considered. Parameters evaluated among the groups included toxicity profiles, reasons for stopping treatment, number of interleukin-2 doses per cycle, and response to therapy. Three patient groups were compared. Group I (n = 27) comprised patients with previously treated brain metastases (surgery or radiation), group 2 (n = 37) comprised patients with untreated brain metastases, and group 3 (n = 1,005) comprised patients without brain metastases. For most comparisons between patients with brain metastases and those without, no significant differences were noted in toxicity profiles or reasons for stopping interleukin-2 therapy. Patients with previously treated brain metastases received fewer interleukin-2 doses per cycle (median, 6.5) than patients with previously untreated brain metastases (median, 7.5) or patients without brain metastases (median, 7.5). Patients with previously treated brain metastases demonstrated an 18.5{\%} overall clinical response to interleukin-2 treatment. However, patients with evaluable (previously untreated) brain metastases had an overall 5.6{\%} response rate, which was less than the 19.8{\%} response rate of patients without brain metastases. Two of thirty-six patients with evaluable brain metastases demonstrated objective regression of intracranial and extracranial disease after receiving interleukin-2. Carefully selected patients with brain metastases can safely receive high-dose interleukin-2, and some can experience a response to treatment at intracranial and extracranial disease sites.",
keywords = "Brain metastases, Interleukin-2, Melanoma, Safety",
author = "Guirguis, {Lisa M.} and Yang, {James C.} and White, {Donald E.} and Steinberg, {Seth M.} and Liewehr, {David J.} and Rosenberg, {Steven A.} and Schwartzentruber, {Douglas J.}",
year = "2002",
doi = "10.1097/00002371-200201000-00009",
language = "English (US)",
volume = "25",
pages = "82--87",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases

AU - Guirguis, Lisa M.

AU - Yang, James C.

AU - White, Donald E.

AU - Steinberg, Seth M.

AU - Liewehr, David J.

AU - Rosenberg, Steven A.

AU - Schwartzentruber, Douglas J.

PY - 2002

Y1 - 2002

N2 - The authors determined the safety and efficacy of recombinant high-dose interleukin-2 administration in patients with brain metastases. This retrospective review included 1,069 patients with metastatic melanoma or renal cell carcinoma who received high-dose interleukin-2 alone or in combination with other immunotherapy or chemotherapy from July 1985-July 2000. All patients were evaluated for both toxicity and response. Only the first exposure to interleukin-2 was considered. Parameters evaluated among the groups included toxicity profiles, reasons for stopping treatment, number of interleukin-2 doses per cycle, and response to therapy. Three patient groups were compared. Group I (n = 27) comprised patients with previously treated brain metastases (surgery or radiation), group 2 (n = 37) comprised patients with untreated brain metastases, and group 3 (n = 1,005) comprised patients without brain metastases. For most comparisons between patients with brain metastases and those without, no significant differences were noted in toxicity profiles or reasons for stopping interleukin-2 therapy. Patients with previously treated brain metastases received fewer interleukin-2 doses per cycle (median, 6.5) than patients with previously untreated brain metastases (median, 7.5) or patients without brain metastases (median, 7.5). Patients with previously treated brain metastases demonstrated an 18.5% overall clinical response to interleukin-2 treatment. However, patients with evaluable (previously untreated) brain metastases had an overall 5.6% response rate, which was less than the 19.8% response rate of patients without brain metastases. Two of thirty-six patients with evaluable brain metastases demonstrated objective regression of intracranial and extracranial disease after receiving interleukin-2. Carefully selected patients with brain metastases can safely receive high-dose interleukin-2, and some can experience a response to treatment at intracranial and extracranial disease sites.

AB - The authors determined the safety and efficacy of recombinant high-dose interleukin-2 administration in patients with brain metastases. This retrospective review included 1,069 patients with metastatic melanoma or renal cell carcinoma who received high-dose interleukin-2 alone or in combination with other immunotherapy or chemotherapy from July 1985-July 2000. All patients were evaluated for both toxicity and response. Only the first exposure to interleukin-2 was considered. Parameters evaluated among the groups included toxicity profiles, reasons for stopping treatment, number of interleukin-2 doses per cycle, and response to therapy. Three patient groups were compared. Group I (n = 27) comprised patients with previously treated brain metastases (surgery or radiation), group 2 (n = 37) comprised patients with untreated brain metastases, and group 3 (n = 1,005) comprised patients without brain metastases. For most comparisons between patients with brain metastases and those without, no significant differences were noted in toxicity profiles or reasons for stopping interleukin-2 therapy. Patients with previously treated brain metastases received fewer interleukin-2 doses per cycle (median, 6.5) than patients with previously untreated brain metastases (median, 7.5) or patients without brain metastases (median, 7.5). Patients with previously treated brain metastases demonstrated an 18.5% overall clinical response to interleukin-2 treatment. However, patients with evaluable (previously untreated) brain metastases had an overall 5.6% response rate, which was less than the 19.8% response rate of patients without brain metastases. Two of thirty-six patients with evaluable brain metastases demonstrated objective regression of intracranial and extracranial disease after receiving interleukin-2. Carefully selected patients with brain metastases can safely receive high-dose interleukin-2, and some can experience a response to treatment at intracranial and extracranial disease sites.

KW - Brain metastases

KW - Interleukin-2

KW - Melanoma

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=0036140228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036140228&partnerID=8YFLogxK

U2 - 10.1097/00002371-200201000-00009

DO - 10.1097/00002371-200201000-00009

M3 - Article

VL - 25

SP - 82

EP - 87

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 1

ER -